6 new oncology trials approved in Europe
 |
Oncology Hero |
6 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week.
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
| Sponsor: Oslo Universitetssykehus HF | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
| Sponsor: Janssen Cilag International | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestMulticenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
| Sponsor: Fundacion PETHEMA | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestAn Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
| Sponsor: Grifols Therapeutics LLC | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestOptimization of De-EscalatiON strategies in early breast cancer (ODEON)
| Sponsor: Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestRandomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases
| Sponsor: Unicancer | Phase: Not specified |
Interested in offering this trial to suitable patients?
Register Investigator InterestOncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high Sponsor: UZ Brussel Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest Randomized study evaluating the impact of an innovative and cooperative pathway integrating OncoGeriatric, pharmaceutical and...
Oncology Hero 10 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study MeetURO and FICOG trial Sponsor: Fondazione IRCCS Istituto Nazionale Dei Tumori Phase: 3 Interested in offering this trial to suitable patients?...
In partnership with Oncology Updates — Aug 26 to Sep 2025 September delivered practice-relevant oncology updates worldwide — guideline shifts, pivotal trial readouts, new approvals, and high-impact AI tools. Below is a concise, clinician-first roundup. 🎗️ 🩺Lung cancer ESMO issues NSCLC guideline for early & locally advanced disease New recommendations standardize biomarker-driven multimodality care in stage I–III NSCLC, including integration of IO/targeted therapy in pathways. Read more...